Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials
Drugs and Drug Candidates · 03.06.2026 · 5 (2) · 35
DOI: 10.3390/ddc5020035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 03.06.2026. Verfasst von Clemilson Berto-Junior und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is a growing public health concern linked to poor dietary habits, physical inactivity, and metabolic disturbances, which can be evaluated using complementary laboratory tests. Among pharmacological interventions, semaglutide, a GLP-1 receptor agonist, has shown promise by acting on the central nervous system to reduce appetite and stimulate insulin secretion, thereby improving the lipid profile and reducing inflammation biomarkers. This review focused on changes in lipid parameters and C-reactive protein (CRP) levels in overweight or obese individuals treated with semaglutide, based on phase 3 studies from the STEP program (“Semaglutide Treatment Effect in People with Obesity”). The STEP clinical trial program was conducted across 36 countries, reflecting a broad and diverse geographic representation. Key findings include significant reductions between placebo vs. semaglutide in body weight (−1.3 vs. −13.0 Kg), body mass index (−0.69 vs. −4.72 kg/m2), and waist circumference (−2.79 × −11.81 cm). Additionally, there were notable decreases in triglycerides (−0.67 vs. −20.89%), VLDL-C (−0.99 vs. 20.82%), and CRP levels (−15.45 vs. −55.55%). These changes reflect improvements in both inflammatory and metabolic markers. The observed benefits suggest that semaglutide may contribute to reducing comorbidities associated with metabolic syndrome and to the prevention of cardiovascular disease. Current evidence also supports its potential role in individualized treatment strategies based on patients’ clinical and biochemical profiles. However, despite these promising findings, further long-term studies are required to confirm the efficacy and safety of semaglutide across diverse populations.
Zitieren
APA
Berto-Junior, C., Blanco, G. G. R., Marcello, L. V., Rangel, G. T., Marques, N. D. C. D. S., Cinelli, L. P., & Cunha-Junior, E. F. D. (2026). Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials. Drugs and Drug Candidates, 5(2), 35. https://doi.org/10.3390/ddc5020035
Vancouver
Berto-Junior C, Blanco GGR, Marcello LV, Rangel GT, Marques NDCDS, Cinelli LP, et al. Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials. Drugs and Drug Candidates. 2026;5(2):35. doi:10.3390/ddc5020035
BibTeX
@article{BertoJunior2026,
author = {Berto-Junior, Clemilson and Blanco, Gabriel Gallo Ribas and Marcello, Lucas Varella and Rangel, Gabriella Terra and Marques, Natália da Conceição dos Santos and Cinelli, Leonardo Paes and Cunha-Junior, Edezio Ferreira da},
title = {Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials},
journal = {Drugs and Drug Candidates},
year = {2026},
volume = {5},
number = {2},
pages = {35},
doi = {10.3390/ddc5020035}
}
EUVIMED